(Total Views: 505)
Posted On: 11/22/2021 2:32:26 PM
Post# of 153986
The Novavax vaccine should work against variants because it includes proteins from the BODY of the virus. Those proteins are unchanging or else it wouldn't be the COVID virus.
Also, Novavax's technology does not use the entire spike. It uses protein segments from the spike. Therefore, if a mutation occurs on one section of the spike, the vaccinee's immune system should still recognize the unchanged protein portions from the spike.
This is not the mRNA technology. It is based on the older technologies.
Whether it lasts longer remains to be seen.
It's unfortunate that there has been NO publicity on how the FDA screwed Novavax, by taking away their manufacturing ability by decertifying the contract plant they were using -- then, the same day, re-certifying it for Pfizer. Then, when Novavax found a plant in South Korea that was already certified for other manufacturing, the FDA refused to send an inspector for months. THAT is why Pfizer and Moderna were first out of the box with vaccines, instead of Novavax, which could have had their vaccine approved first if not for the FDA.
And that's why NVAX has been submitting applications and getting contracts worldwide -- Japan, New Zealand, UK, EU, Canada, various Latin American and African and Asian countries -- but has not submitted to the U.S. FDA. They say, maybe, by the end of the year, maybe.
Who can blame them for going where they know they'll be approved first, and then the weight of public opinion will FORCE the FDA to approve.
Also, Novavax's technology does not use the entire spike. It uses protein segments from the spike. Therefore, if a mutation occurs on one section of the spike, the vaccinee's immune system should still recognize the unchanged protein portions from the spike.
This is not the mRNA technology. It is based on the older technologies.
Whether it lasts longer remains to be seen.
It's unfortunate that there has been NO publicity on how the FDA screwed Novavax, by taking away their manufacturing ability by decertifying the contract plant they were using -- then, the same day, re-certifying it for Pfizer. Then, when Novavax found a plant in South Korea that was already certified for other manufacturing, the FDA refused to send an inspector for months. THAT is why Pfizer and Moderna were first out of the box with vaccines, instead of Novavax, which could have had their vaccine approved first if not for the FDA.
And that's why NVAX has been submitting applications and getting contracts worldwide -- Japan, New Zealand, UK, EU, Canada, various Latin American and African and Asian countries -- but has not submitted to the U.S. FDA. They say, maybe, by the end of the year, maybe.
Who can blame them for going where they know they'll be approved first, and then the weight of public opinion will FORCE the FDA to approve.
(8)
(0)
